SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Order online now!

www.rockland.com
tech@rockland.com
+1 484.791.3823

Datasheet for 009-001-P24

AKT3 Human Recombinant Protein

Overview

Description:	AKT3 Human Recombinant Protein - 009-001-P24
Item No.:	009-001-P24
Size:	10 µg
Applications:	SDS-PAGE, WB
Origin:	Human

Product Details

Background:	AKT3 is a component of the PI-3 kinase pathway and is activated by phosphorylation at Ser 473 and Thr 308. AKT is a cytoplasmic protein also known as Protein Kinase B (PKB) and RAC (Related to A and C kinases). AKT is a key regulator of many signal transduction pathways, and it exhibits tight control over cell proliferation and cell viability. Overexpression or inappropriate activation of AKT is noted in many types of cancer. AKT mediates many of the downstream events of PI 3-kinase (a lipid kinase activated by growth factors, cytokines and insulin). PI 3-kinase recruits AKT to the membrane, where it is activated by PDK1 phosphorylation. Once phosphorylated, AKT dissociates from the membrane and phosphorylates targets in the cytoplasm and the cell nucleus. AKT has two main roles: (i) inhibition of apoptosis; (ii) promotion of proliferation. AKT3 recombinant protein is ideal for investigators involved in Cell Signaling, Neuroscience and Signal Transduction research.
Synonyms:	RAC, PKB, AKT, PKB gamma
Species of Origin:	Human
Type:	Recombinant Protein

Target Details

Gene Name:	AKT3
Purity/Specificity:	Recombinant protein corresponds to amino acids 1 to 481 of mature human AKT3; Akt isoform 3. The recombinant protein contains a polyhistidine affinity tag at the amino terminus. This protein was co-expressed with the p110 kinase domain leading to phosphorylation of key residues T308 and S473. Purity is greater than 90% as determined by reducing and non-reducing SDS-PAGE and by analytical HPLC.

Relevant Links:	• UniProtKB - Q9Y243 • GeneID - 10000 • NCBI - NP_001193658.1

Application Details

Tested Applications:	SDS-PAGE, WB
Application Note:	Human AKT3 recombinant protein has been tested in western blot and SDS-Page and is suitable as a control for polyclonal or monoclonal anti-AKT3 in immunological assays. Akt3 recombinant protein is expected to be phosphorylated and in an active state. It is well suited as a control for anti-AKT pT308 which detects phosphorylated T308 residue, and anti-AKT pS473, that detects phosphorylated S473. For western blot use at 50 ng or less. For other assays concentration is user optimized.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
WB:	50ng

Formulation

Physical State:	Liquid
Concentration:	1.03mg/ml by UV absorbance at 280 nm
Buffer:	20 mM Tris pH8, 300 mM NaCl with 10% glycerol
Preservative:	None
Stabilizer:	10% (v/v) Glycerol

Shipping & Handling

Shipping Condition:	Dry Ice
Storage Condition:	Store vial at -70° C prior to use. Thaw only prior to immediate use. Maintain sterility. This product DOES NOT contain preservative. DO NOT VORTEX. For long term storage we recommend adding a carrier protein such as HSA or BSA to 0.1% (i.e. 1.0 mg/mL) . For best results aliquot contents and freeze at -20° C or colder. Avoid cycles of freezing and thawing. Centrifuge vial before each opening to dislodge contents from the cap and to clarify if contents are not clear after standing at room temperature.
Expiration:	Expiration date is one (1) year from date of receipt.

Images



SDS-PAGE
SDS-PAGE of AKT3 Human Recombinant Protein. Lane 1: AKT3, unreduced. Lane 2: prestained MW markers. Lane 3: AKT3, reduced. Load: 1 µg per lane. Predicted/Observed size: 56 kDa, ~56 kDa for AKT3. Other band(s):unreduced band at 65 kDa is alternate fold for AKT3.



Western Blot
Western Blot of AKT3 Human Recombinant Protein Lane 1: SuperSignal MW markers. Lane2: AKT3. Load: 50 ng per lane. Primary antibody: AKT3 antibody at 1:1,000 overnight at 4°C. Secondary antibody: Peroxidase mouse secondary antibody at 1:20,000 for 1 hour at room temperature. Block: Blocking Buffer for Fluorescent Western Blotting (MB-070), 1 hour at room temperature. Predicted/Observed size: 56kDa, 56kDa for AKT3. Other band(s): none.



Western Blot
Western Blot of Rabbit AKT Antibodies. Lane 1: NIR MW protein ladder. Lane 2: AKT1, recombinant: 009-001-P21. Lane 3: AKT1, phosphatase-treated: 009-001-I51. Lane 4: AKT1, mutant T308A/S473A: 009-001-P22. Lane 5: AKT2, recombinant: 009-001-P23. Lane 6: AKT2, phosphatase-treated: 009-001-E71. Lane 7: AKT3, recombinant: 009-001-P24. Lane 8: AKT3, phosphatase-treated: 009-001-E75. Load: 50ng per lane. Blot A: 600-401-269 Anti-Akt pT308 used at 1:2270, Blot B: 100-401-401 Anti-Akt used 1:1000.

www.rockland.com
tech@rockland.com
+1 484.791.3823

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.